178 related articles for article (PubMed ID: 22871047)
1. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
3. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
4. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
Ho CM; Lin MC; Huang SH; Huang CJ; Lai HC; Chien TY; Chang SF
Gynecol Oncol; 2009 Feb; 112(2):307-13. PubMed ID: 19007975
[TBL] [Abstract][Full Text] [Related]
5. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
[TBL] [Abstract][Full Text] [Related]
6. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
8. Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer.
Gong Y; Guo MZ; Ye ZJ; Zhang XL; Zhao YL; Yang YS
World J Gastroenterol; 2011 Jan; 17(4):526-33. PubMed ID: 21274384
[TBL] [Abstract][Full Text] [Related]
9. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer.
Yu Y; Yin D; Hoque MO; Cao B; Jia Y; Yang Y; Guo M
Tumour Biol; 2012 Apr; 33(2):307-14. PubMed ID: 22095135
[TBL] [Abstract][Full Text] [Related]
10. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Hirasawa A; Saito-Ohara F; Inoue J; Aoki D; Susumu N; Yokoyama T; Nozawa S; Inazawa J; Imoto I
Clin Cancer Res; 2003 Jun; 9(6):1995-2004. PubMed ID: 12796361
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
[TBL] [Abstract][Full Text] [Related]
13. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer.
Guo M; Ren J; Brock MV; Herman JG; Carraway HE
Epigenetics; 2008 Nov; 3(6):336-41. PubMed ID: 19098448
[TBL] [Abstract][Full Text] [Related]
15. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.
Krop I; Player A; Tablante A; Taylor-Parker M; Lahti-Domenici J; Fukuoka J; Batra SK; Papadopoulos N; Richards WG; Sugarbaker DJ; Wright RL; Shim J; Stamey TA; Sellers WR; Loda M; Meyerson M; Hruban R; Jen J; Polyak K
Mol Cancer Res; 2004 Sep; 2(9):489-94. PubMed ID: 15383627
[TBL] [Abstract][Full Text] [Related]
16. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD
Clin Cancer Res; 2011 Apr; 17(8):2538-48. PubMed ID: 21343371
[TBL] [Abstract][Full Text] [Related]
17. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
19. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival.
Li B; Jin H; Yu Y; Gu C; Zhou X; Zhao N; Feng Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1347-52. PubMed ID: 20009888
[TBL] [Abstract][Full Text] [Related]
20. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]